scholarly journals Cell Responses to Electrical Pulse Stimulation for Anticancer Drug Release

Materials ◽  
2019 ◽  
Vol 12 (16) ◽  
pp. 2633 ◽  
Author(s):  
Anna Puiggalí-Jou ◽  
Luis J. del Valle ◽  
Carlos Alemán
Keyword(s):  
Electrical Stimulation ◽  
Drug Release ◽  
Anticancer Drug ◽  
Smart Materials ◽  
Controlled Drug Release ◽  
Electrical Stimulus ◽  
Operating Conditions ◽  
The Body ◽  
Electrical Pulse Stimulation ◽  
Drug Molecules

Electrical stimulation is an attractive approach to tune on-demand drug release in the body as it relies on simple setups and requires typically 1 V or less. Although many studies have been focused on the development of potential smart materials for electrically controlled drug release, as well as on the exploration of different delivery mechanisms, progress in the field is slow because the response of cells exposed to external electrical stimulus is frequently omitted from such investigations. In this work, we monitor the behavior of prostate and breast cancer cells (PC-3 and MCF7, respectively) exposed to electroactive platforms loaded with curcumin, a hydrophobic anticancer drug. These consist in conducting polymer nanoparticles, which release drug molecules by altering their interactions with polymer, and electrospun polyester microfibres that contain electroactive nanoparticles able to alter the porosity of the matrix through an electro-mechanical actuation mechanism. The response of the cells against different operating conditions has been examined considering their viability, metabolism, spreading and shape. Results have allowed us to differentiate the damage induced in the cell by the electrical stimulation from other effects, as for example, the anticancer activity of curcumin and/or the presence of curcumin-loaded nanoparticles or fibres, demonstrating that these kinds of platforms can be effective when the dosage of the drug occurs under restricted conditions.

Nanostructured Ketorolac-Tromethamine/MCF: Synthesis, Characterization and Application in Drug Release System

2018 ◽  
Vol 14 (5) ◽  
pp. 432-439 ◽  
Author(s):  
Juliana M. Juarez ◽  
Jorgelina Cussa ◽  
Marcos B. Gomez Costa ◽  
Oscar A. Anunziata
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Therapeutic Efficacy ◽  
Drug Delivery Systems ◽  
Controlled Drug Release ◽  
Delivery Systems ◽  
The Body ◽  
Fickian Diffusion ◽  
Ketorolac Tromethamine

Background: Controlled drug delivery systems can maintain the concentration of drugs in the exact sites of the body within the optimum range and below the toxicity threshold, improving therapeutic efficacy and reducing toxicity. Mesostructured Cellular Foam (MCF) material is a new promising host for drug delivery systems due to high biocompatibility, in vivo biodegradability and low toxicity. Methods: Ketorolac-Tromethamine/MCF composite was synthesized. The material synthesis and loading of ketorolac-tromethamine into MCF pores were successful as shown by XRD, FTIR, TGA, TEM and textural analyses. Results: We obtained promising results for controlled drug release using the novel MCF material. The application of these materials in KETO release is innovative, achieving an initial high release rate and then maintaining a constant rate at high times. This allows keeping drug concentration within the range of therapeutic efficacy, being highly applicable for the treatment of diseases that need a rapid response. The release of KETO/MCF was compared with other containers of KETO (KETO/SBA-15) and commercial tablets. Conclusion: The best model to fit experimental data was Ritger-Peppas equation. Other models used in this work could not properly explain the controlled drug release of this material. The predominant release of KETO from MCF was non-Fickian diffusion.

scholarly journals Actively Targeted and Redox Responsive Delivery of Anticancer Drug by Chitosan Nanoparticles

Pharmaceutics ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 26 ◽  
Author(s):  
Elisabetta Mazzotta ◽  
Selene De Benedittis ◽  
Antonio Qualtieri ◽  
Rita Muzzalupo
Keyword(s):  
Drug Release ◽  
Cancer Cells ◽  
Anticancer Drug ◽  
Water Solubility ◽  
Chitosan Nanoparticles ◽  
Controlled Drug Release ◽  
Dependent Manner ◽  
High Concentration ◽  
Redox Responsive

The clinical efficacy of methotrexate (MTX) is limited by its poor water solubility, its low bioavailability, and the development of resistance in cancer cells. Herein, we developed novel folate redox-responsive chitosan (FTC) nanoparticles for intracellular MTX delivery. l-Cysteine and folic acid molecules were selected to be covalently linked to chitosan in order to confer it redox responsiveness and active targeting of folate receptors (FRs). NPs based on these novel polymers could possess tumor specificity and a controlled drug release due to the overexpression of FRs and high concentration of reductive agents in the microenvironment of cancer cells. Nanoparticles (NPs) were prepared using an ionotropic gelation technique and characterized in terms of size, morphology, and loading capacity. In vitro drug release profiles exhibited a glutathione (GSH) dependence. In the normal physiological environment, NPs maintained good stability, whereas, in a reducing environment similar to tumor cells, the encapsulated MTX was promptly released. The anticancer activity of MTX-loaded FTC-NPs was also studied by incubating HeLa cells with formulations for various time and concentration intervals. A significant reduction in viability was observed in a dose- and time-dependent manner. In particular, FTC-NPs showed a better inhibition effect on HeLa cancer cell proliferation compared to non-target chitosan-based NPs used as control. The selective cellular uptake of FTC-NPs via FRs was evaluated and confirmed by fluorescence microscopy. Overall, the designed NPs provide an attractive strategy and potential platform for efficient intracellular anticancer drug delivery.

scholarly journals Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

2022 ◽  
Vol 11 ◽  
Author(s):  
Zhengyang Yang ◽  
Wei Deng ◽  
Xiao Zhang ◽  
Yongbo An ◽  
Yishan Liu ◽  
...  
Keyword(s):  
Drug Release ◽  
Cycle Time ◽  
Targeted Delivery ◽  
Biomedical Applications ◽  
Controlled Drug Release ◽  
Complementary Therapy ◽  
The Body ◽  
Drug Bioavailability ◽  
Angiogenic Therapy ◽  
Promising Target

Digestive tumours, a common kind of malignancy worldwide, have recently led to the most tumour-related deaths. Angiogenesis, the process of forming novel blood vessels from pre-existing vessels, is involved in various physiological and pathological processes in the body. Many studies suggest that abnormal angiogenesis plays an important role in the growth, progression, and metastasis of digestive tumours. Therefore, anti-angiogenic therapy is considered a promising target for improving therapeutic efficacy. Traditional strategies such as bevacizumab and regorafenib can target and block the activity of proangiogenic factors to treat digestive tumours. However, due to resistance and some limitations, such as poor pharmacokinetics, their efficacy is not always satisfactory. In recent years, nanotechnology-based anti-angiogenic therapies have emerged as a new way to treat digestive tumours. Compared with commonly used drugs, nanoparticles show great potential in tumour targeted delivery, controlled drug release, prolonged cycle time, and increased drug bioavailability. Therefore, anti-angiogenic nanoparticles may be an effective complementary therapy to treat digestive tumours. In this review, we outline the different mechanisms of angiogenesis, the effects of nanoparticles on angiogenesis, and their biomedical applications in various kinds of digestive tumours. In addition, the opportunities and challenges are briefly discussed.

IONOTROPIC TRAPPING LECITHIN BASED CILOSTAZOL NANOCOCHLEATES FOR DRUG DELIVERY APPLICATIONS

INDIAN DRUGS ◽  
2017 ◽  
Vol 54 (09) ◽  
pp. 24-32
Author(s):  
V. S Katoriya ◽  
◽  
G. S. Deokar ◽  
S. J. Kshirsagar
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Controlled Drug Release ◽  
In Vitro Drug Release ◽  
Drug Molecules ◽  
Study Results ◽  
Phosphodiesterase Iii Inhibitor ◽  
Zero Order Release ◽  
Trapping Method

The nanocochleate drug delivery is based on encapsulating drugs in multilayered lipid crystal matrix (a cochleate) to potentially deliver the drug safely and effectively through the lipoidal membrane. Cilostazol is approved for the treatment of intermittent claudication and used as fibrinolytic agent, platelet aggregation inhibitor, bronchodilator agent, phosphodiesterase III Inhibitor and vasodilator agent. therefore, this drug delivery is suitable to deliver drug molecules into blood vessels. Formulations with lecithin showed good in vitro drug release, drug entrapment study results and the drug in formulations was found to be intact and compatible with lipids used. Two optimized formulations containing cilostazol lecithin-cholesterol showed Korsemayer peppas model perfect zero order release and showed better sustained and controlled drug release. Lecithin-cholesterol nanocochleates prepared by external ionotropic trapping method was found to be better ionic cross linking of drug-lipids particles. Therefore, ionotropic cross-linked particles are promising carriers for oral controlled release dosage forms.

Polymeric advanced delivery systems for antineoplasic drugs: doxorubicin and 5-fluorouracil

e-Polymers ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. 359-372 ◽  
Author(s):  
Luis Jesús Villarreal-Gómez ◽  
Aracely Serrano-Medina ◽  
Erick José Torres-Martínez ◽  
Graciela Lizeth Perez-González ◽  
José Manuel Cornejo-Bravo
Keyword(s):  
Drug Release ◽  
Circulatory System ◽  
Controlled Drug Release ◽  
Delivery Systems ◽  
The Body ◽  
Advantages And Disadvantages ◽  
Site Of Action ◽  
Low Toxicity ◽  
The Right ◽  
Selection Of

AbstractConventional pharmaceuticals generally display the inability to transport active ingredients directly to specific regions of the body, amongst some of their main limitations. The distribution of the drugs in the circulatory system may lead to undesired toxicity, and therefore, adverse reactions. To address this situation, a selective transport of drugs is required, that is, releasing drugs specifically to the site of action in appropriate concentrations and in the right time. To achieve this goal, it is necessary to develop delivery systems that respond to several features, such as low toxicity, optimum properties for the transport and release of the drug, as well as a long half-life in the body. This feature paper critically provides an overview of different strategies of controlled drug release for two model antineoplasic drugs, i.e. doxorubicin (DOX) and 5-fluorouracil (5-FU). Any of the presented strategies for drug release possess advantages and disadvantages, and the selection of the strategy used will depend on the targeted tissue and nature of the drug.

Controlled Drug Release Property of Nano-Porous Silica Micro Particles and their Cytocompatibility

2018 ◽  
Vol 782 ◽  
pp. 262-267
Author(s):  
Yuko Era ◽  
Eri Seitoku ◽  
Ko Nakanishi ◽  
Yosuke Bando ◽  
Koichi Nakamura ◽  
...  
Keyword(s):  
Drug Release ◽  
Glass Ionomer Cement ◽  
Porous Silica ◽  
Controlled Drug Release ◽  
Glass Ionomer ◽  
Drug Molecules ◽  
Micro Particles ◽  
Silica Microparticles ◽  
Model Drug ◽  
Ionomer Cement

In this study, we investigated in cytocompativility and controlled release behavior of a model drug from nanoporous silica microparticles (NPSM). When Mouse osteoblastic cells (MC3T3-E1) were exposed to NPMSs, they indicated excellent cell viability. From NPSM contained in dental glass ionomer cement (NPMS-GIC), they can release cationic model drug molecules gradually in water for 2 weeks when they were contained in GIC. In contrast, GIC without NPSM specimens released the molecule only a couple of days. In the case of inionic molecules, their release were alos determined only a couple of days. These results suggest that NPSM can be used as a sustainable drug-release system in dental and medical fields

scholarly journals POTENTIAL USE OF MANGO GUM (MANGIFERA INDICA) IN PHARMACOLOGICAL SYSTEMS

2019 ◽  
Vol 16 (33) ◽  
pp. 688-706
Author(s):  
M. C. A. SILVEIRA ◽  
R. S. L. GLÓRIA ◽  
K. M. BARBOSA ◽  
L. S. S. SANTOS
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Mangifera Indica ◽  
Controlled Drug Release ◽  
The Body ◽  
Production Costs ◽  
Extraction And Purification ◽  
Acacia Gum ◽  
Alternative Drug ◽  
Pharmaceutical Properties

The possibility of using natural or modified polymers to formulate drug-containing nanocapsules is a pharmaceutical option for cases in which an increase in the half-life of medications in the body and a decrease in side effects is required, and may also be used for better pharmacological targeting of the site. Related to low production costs with these characteristics and renewable availability. Gums and mucilages have been studied for use in natural alternative drug delivery systems. The gum from the trunk of Mangifera indica has few studies aimed at this purpose, although it has shown promising results in previous studies. Characterization of the gum formation pathways are explained, as well as their extraction and purification. The similarity of properties of Acacia gum widely used in tablet blends has been confirmed. Mangifera indica gum was also used for accelerated drug release. The versatility of this gum is associated with the presence of mucilage. Chemical modifications of the Mangifera indica gum and mixtures among other gums may be made to adapt their properties to the various forms of controlled drug release. Several isolated compounds with pharmaceutical properties are demonstrated. Physical chemical characteristics of several articles on this gum have been compiled. The techniques already used for the formation of nanocapsules through Mangifera indica gum are presented. Several studies have been reported specifically using Mangifera indica gum from the Mango trunk used as drug release. These studies justify a summary of the pharmaceutical properties for drug delivery already performed with this gum. Complementary studies for utilization and valorization of Mango cultivation are suggested.

Formulation, Design and Development of Niosome Based Topical Gel for Skin Cancer

2017 ◽  
Vol 2 (3) ◽  
Keyword(s):  
Skin Cancer ◽  
Drug Release ◽  
Hemorrhagic Cystitis ◽  
The Body ◽  
Cancer Drug ◽  
Inversion Method ◽  
Body Parts ◽  
Basal Cells ◽  
Formulation Design ◽  
Topical Gel

Melanoma is the most dangerous type of skin cancer in which mostly damaged unpaired DNA starts mutating abnormally and staged an unprecedented proliferation of epithelial skin to form a malignant tumor. In epidemics of skin, pigment-forming melanocytes of basal cells start depleting and form uneven black or brown moles. Melanoma can further spread all over the body parts and could become hard to detect. In USA Melanoma kills an estimated 10,130 people annually. This challenge can be succumbed by using the certain anti-cancer drug. In this study design, cyclophosphamide were used as a model drug. But it has own limitation like mild to moderate use may cause severe cytopenia, hemorrhagic cystitis, neutropenia, alopecia and GI disturbance. This is a promising challenge, which is caused due to the increasing in plasma drug concentration above therapeutic level and due to no rate limiting steps involved in formulation design. In this study, we tried to modify drug release up to threefold and extended the release of drug by preparing and designing niosome based topical gel. In the presence of Dichloromethane, Span60 and cholesterol, the initial niosomes were prepared using vacuum evaporator. The optimum percentage drug entrapment efficacy, zeta potential, particle size was found to be 72.16%, 6.19mV, 1.67µm.Prepared niosomes were further characterized using TEM analyzer. The optimum batch of niosomes was selected and incorporated into topical gel preparation. Cold inversion method and Poloxamer -188 and HPMC as core polymers, were used to prepare cyclophosphamide niosome based topical gel. The formula was designed using Design expert 7.0.0 software and Box-Behnken Design model was selected. Almost all the evaluation parameters were studied and reported. The MTT shows good % cell growth inhibition by prepared niosome based gel against of A375 cell line. The drug release was extended up to 20th hours. Further as per ICH Q1A (R2), guideline 6 month stability studies were performed. The results were satisfactory and indicating a good formulation approach design was achieved for Melanoma treatment.

Sign in / Sign up

Export Citation Format

Share Document